Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · RIGEL PHARMACEUTICALS INC (RIGL)

Rigel Pharmaceuticals names Alison Hannah Chief Medical Officer, replacing Lisa Rojkjaer

Neutral Impact 4 of 5 leadership Written later

Rigel Pharmaceuticals appointed director Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer effective July 1, 2026, and she resigned from the Board at the same time. The filing also says Lisa Rojkjaer, M.D. left the Chief Medical Officer role and the company effective June 25, 2026, so the change is a leadership transition in a key clinical position.

Key points

  • Alison L. Hannah, M.D. appointed Executive Vice President and Chief Medical Officer on July 1, 2026
  • Dr. Hannah resigned from the Board of Directors effective July 1, 2026; she had served on the Board since May 2021
  • Lisa Rojkjaer, M.D. ceased to be Executive Vice President and Chief Medical Officer and separated from the company effective June 25, 2026

The filing

CompanyRIGEL PHARMACEUTICALS INC (RIGL)
Form8-K, current report
Filed with the SECJul 1, 2026, 4:11 PM ET
Accession number0001034842-26-000045

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.